April 1, 2021
Two distinct diagnostic tests, a host/pathogen RNA sequencing platform, and spatially resolved tissue mapping tools, were created by a multidisciplinary team of Weill Cornell Medicine and NewYork-Presbyterian Hospital-led researchers and used to map SARS-CoV-2 infections at the height of the initial COVID-19 outbreak in New York City.These alternatives to the gold standard RT-PCR test expand the repertoire of tools available to the public health community and together offer the benefits of speed, simplicity and in-depth knowledge about the virus.
March 2, 2021
We are delighted to announce the promotion of Luigi Marchionni, MD, PhD, to Vice Chair, Computational and Systems Pathology effective March 1, 2021.Luigi Marchionni, MD, PhD Vice Chair, Computational and Systems PathologyDr. Marchionni is truly an outstanding computational biologist. He works to develop novel tools for integration and analysis of “omics” data from distinct patients, model organisms, and technological platforms. Dr. Marchionni’s research, through the integration of multi-modal data, aims at the development of novel prediction algorithms for disease prognostication and therapy...
February 23, 2021
Antibodies that guard against COVID-19 can transfer from mothers to babies while in the womb, according to a new study from Weill Cornell Medicine and NewYork-Presbyterian researchers published in the American Journal of Obstetrics and Gynecology.This discovery, published Jan. 22, adds to growing evidence that suggests that pregnant women who generate protective antibodies after contracting the coronavirus often convey some of that natural immunity to their fetuses. The findings also lend support to the idea that vaccinating mothers-to-be may also have benefits for their newborns. Yawei (...
February 22, 2021
A gene linked to unusually long lifespans in humans protects brain stem cells from the harmful effects of stress, according to a new study by Weill Cornell Medicine investigators.Studies of humans who live longer than 100 years have shown that many share an unusual version of a gene called Forkhead box protein O3 (FOXO3). That discovery led Dr. Jihye Paik, associate professor of pathology and laboratory medicine at Weill Cornell Medicine, and her colleagues to investigate how this gene contributes to brain health during aging.Jihye Paik, PhD Associate Professor of Pathology and Laboratory...
January 17, 2021
The Starr Cancer Consortium has awarded grant funding to three Weill Cornell Medicine-led multi-institution teams to advance their groundbreaking cancer research projects. The grants will support studies on mechanisms that drive lymphoma and urothelial cancers, and the effects of radiation therapy.Steven Josefowicz, PhD Assistant Professor of Pathology and Laboratory MedicineEstablished by the Starr Foundation in 2006, the Starr Cancer Consortium is a collaboration among five leading research institutions: The Broad Institute of MIT and Harvard, Cold Spring Harbor Laboratory, Memorial Sloan...
December 10, 2020
Mutations in proteins called histone H1, which help package DNA in chromosomes, are a frequent cause of lymphomas, according to a study led by researchers at Weill Cornell Medicine, NewYork-Presbyterian and The Rockefeller University. The findings could lead to new approaches to treating these cancers.
December 7, 2020
Teresa Sanchez, Ph.D., Assistant Professor of Pathology and Laboratory Medicine, was featured twice on the website of the influential North American Vascular Biology Organization (NAVBO) during the month of November, 2020. Teresa Sanchez, PhDAssistant Professor of Pathology and Laboratory Medicine The Members' Labs page of the website highlighted her primary research, which investigates the molecular mechanisms governing endothelial dysfunction in various pathological conditions such as cerebrovascular diseases (e.g., ischemic stroke, subarachnoid hemorrhage) and sepsis. The NAVBO Education...
November 22, 2020
Common symptoms of the genetic disorder neurofibromatosis type 1 (NF1), including skeletal fragility and the loss of bone mass, may be treatable with an existing anti-cancer drug, according to a study from researchers at Weill Cornell Medicine. The findings reveal the potential for an expanding array of therapeutic options for patients who have this difficult-to-treat condition.Matthew B. Greenblatt, MD, PhDAssociate Professor of Pathology and Laboratory MedicineThe study, published Nov. 11 in Nature Communications, uncovered a signaling pathway in bone-making cells that helps drive the...
November 22, 2020
Molecular changes in cells called fibroblasts, which help provide support for tissues throughout the body, may explain why one type of colon cancer doesn’t respond to therapy, according to a team of researchers from Weill Cornell Medicine. Targeting these cells may be a way to make treatment more effective.Jorge Moscat, PhDProfessor of Pathology and Laboratory MedicineIn a study published Nov. 17 in Developmental Cell the investigators examined cells called fibroblasts in CMS4, the most aggressive and difficult-to-treat form of colorectal cancer, to determine how these cancer-associated cells...
November 16, 2020
Congratulations to Dr. Massimo Loda for receiving the Meritorious Achievement Award from the Society for Basic Urologic Research (SBUR).